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INTRODUCTION
In addition to its well-known renal effects aldosterone 
(Aldo) exerts cardiac actions such as blood pressure-
independent cardiac fibrosis1 and left ventricular (LV) 
enlargement1. Apart from these presumably genomic 
effects, Aldo elicits rapid nongenomically-mediated 
effects2; it acutely increases systemic vascular resis-
tance3, decreases cardiac output4 and increases atrial 
myocardial monophasic action potential duration 
within minutes after intravenous iv application5.
We like to report a serendipitous finding that came 
to our attention, a positive correlation and a linear re-
gression between LV contraction duration and plasma 
Aldo levels that do not seem to have yet been reported 
in the literature. This correlation was found during 
our investigation of the effects of endogenous vaso-
active substances [Atrial Natriuretic Peptide (ANP) 
and Brain Natriuretic Peptide (BNP)] on cardiovascu-
lar and hormonal parameters in healthy anesthetized 
male New Zealand White (NZW) rabbits.
In this paper we describe the experimental proto-
col as well as the findings and the statistical results 
that guided us to the above correlation and we attempt 
its interpretation on the basis of other investigators re-
sults for Aldo actions.
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MeThODS
Twenty five New Zealand White (NZW) male rabbits 
with body weight (BW): 3600 ± 485 g [corresponding 
to an age range of 16 to 26 wk6] and hematocrit (Ht): 
33±6% (X  ± SD) were used, raised in our Department 
in all-metal wire floor-type hutches and given food 
and water ad libitum. The calculated daily Na+ intake 
was 23 - 30 mEq. Under urethane (Sigma®) anesthesia 
(1.5g/kg BW iv) the left ventricle of the heart and the 
left carotid and femoral arteries were cannulated for 
left ventricular pressure (LVP) and blood pressure 
(BP) recordings, with concurrent ECG tracing. Under 
urethane anaesthesia both the parasympathetic and the 
sympathetic sections of the autonomic nervous sys-
tem are tonically active in controlling resting cardio-
vascular parameters7. Central venous pressure (CVP) 
was also recorded and blood samples for ANP, plasma 
renin activity (PRA) and Aldo levels were taken from 
the cannulated right jugular vein. The catheters used 
were siliconized nasogastric radiopaque tubes 6CH 
filled with heparinized saline 1,000U/ml.
Carotid and femoral BP and LVP were recorded 
simultaneously via Gould P23XL pressure transduc-
ers in a Vital Signs Monitor (Physiocontrol® VSM4), 
while a TSD 104A blood pressure transducer of 
Biopac® was used for CVP recording. Data acquisi-
tion was performed by the aid of MP100 Work Sta-
tion for Windows (MP100WSW-Biopac®). All trac-
ings were recorded by a sample rate of 200 samples/
sec and lasted 15 sec. From LVP, the left ventricular 
maximal (systolic) pressure (LVPmax), the left ven-
tricular end diastolic pressure (LVEDP), the maximal 
and the minimal change over time in LV pressure (LV-
maxdp/dt and LVmindp/dt) and the Δd [time interval 
between LVmaxdp/dt and LVmindp/dt = contraction 
duration, measured as was described by Yamamoto et 
al8] were estimated by the aid of Acqknowledge 3.2.4® 
software. LVPmax was estimated as the mean LVP-
max of a 15 sec tracing and LVEDP was calculated 
as the pressure corresponding to the beginning of the 
LVP upstroke (mean value of LVEDP of 5 consecutive 
cardiac cycles). LVmaxdp/dt (index of LV contractil-
ity during isovolumic contraction) and LVmindp/dt 
(index of isovolumic relaxation) were estimated from 
the 1st derivative (dp/dt) of the LVP (a new tracing 
resulting, by the aid of Acqknowledge 3.2.4®, from 
the LVP tracing) (Figure 1). By the aid this software 
all maximal positive peaks and all maximal negative 
peaks of the 15 sec tracing were added and LVmaxdp/
dt and LVmindp/dt were estimated as their mean val-
ues respectively. From the carotid artery blood pres-
sure tracing, the left ventricular ejection time (LVET) 
was also estimated, as the time from the upstroke of 
the left carotid arterial pulse to dicrotic notch (mean 
value of LVET of 5 consecutive cardiac cycles) and 
the Double Product [DP, (heart rate X systolic blood 
pressure- HR x SBP)] was calculated as index of heart 
work. Heart rate (HR) was calculated as the mean 
HR of a 15sec ECG tracing, after smoothing of the 
ECG with a digital filter [Low Pass Finite Impulse Re-
sponse (FIR) filter] Blackman -67db (cutoff frequency 
20Hz), for noise removal. The ECG was monitored 
from standard EEG lead II. Mean blood pressure 
(MBP) was calculated as the ratio of the integral of 
pulse pressure (PP) tracing by the duration of the car-
diac cycle [integral of all pulse pressures of the 15 sec 
tracing divided by the recording time (15 sec)].
Pulse wave velocity (PWV), which is inversely re-
lated to distensibility, was used as parameter of aorta 
stiffness. PWV was calculated according to the meth-
od of Hirata et al9 as the ratio of the distance from the 
carotid artery to the femoral artery (distance between 
the recording sites: 30-37 cm according to animal 
size), to the time required for the pulse wave to travel 
from the carotid to the femoral artery, i.e. the differ-
Figure 1. Concurrent recordings of ECG, LVP and its de-
rived dp/dt tracing, for the measurement of LVmaxdp/dt, 
LVmindp/dt, Δd and LVEDP. (LVmaxdp/dt = upper trac-
ing, upper arrow, LVmindp/dt = upper tracing, lower arrow, 
Δd = dashed area between LVmaxdp/dt and LVmindp/dt, 
LVEDP = lower tracing, arrow).
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ence of two times, the time from the beginning of the 
QRS to the beginning of the left femoral arterial pulse 
and the time from the beginning of the QRS to the 
upstroke of the left carotid arterial pulse.
A solution of 0.9% NaCl [normal saline (N/S)] was 
iv infused (by an ear vein) to the extent of 1% of body 
weight as priming infusion and then was followed by 
sustaining infusion at a rate 0.5 ml/kg/min during the 
whole experimental period. After the cannulation of 
the vessels and the ventricle, an acclimatization pe-
riod of 30 min was allowed and thereafter recordings 
and blood samples for hormone measurement were 
taken. Blood (3,0 ml) was taken in prefrozen tubes 
containing 1mg/ml K3EDTA and 500 U/ml aprotinine 
(protease inhibitor) and was centrifuged at 1,040 g for 
15 min at 4oC to provide plasma for hormone mea-
surement. The plasma was then removed and stored 
at -20 0C for subsequent analysis by RIA. ANP levels 
were measured by hANP (1-28) RIA kit of Bachem® 
(specificity 100% for hANP and rabbit ANP, sensitivi-
ty 5 pg/tube, intrassay variation 6.5%, interassay vari-
ation 10.5%) while PRA and Aldo were measured by 
RIA kits of Radim® (PRA RIA kit specificity 100% 
for angiotensin I, sensitivity 0.15 ng/tube, intrassay 
variation 5.4%, interassay variation 7.7%, Aldo RIA 
kit specificity 100% for Aldo, sensitivity 8.8 pg/tube, 
intrassay variation 6.6%, interassay variation 8.4%). 
All experiments were done at the same diurnal time 
interval (10.00-14.00).
Local Veterinary Ethical Committee approved the 
study, as it was in accordance with the 86/609 Euro-
pean Union Council order.
Descriptive statistics was used for presenting data. 
All values are expressed as mean ± standard deviation 
(X  ± SD). Correlations of Δd and Aldo with other 
cardiovascular parameters were performed as well as 
stepwise regression analysis to evaluate potentially 
confounding factors independently contributing to Δd. 
Statistical significance accepted at the α = 5% level 
except for stepwise regression procedure, where an α 
= 10% boundary was set to minimize type II errors. 
Statistical analysis was performed using the JMP IN 
statistical computer program.
ReSUlTS
The results of cardiovascular parameters and vasoac-
tive hormone levels are shown in Table 1.
Correlations of Δd with other cardiovascular pa-
rameters are shown in table 2, whereas in table 3 cor-
relations of Aldo with other cardiovascular parameters 
are shown. There is a linear regression between Δd and 
Aldo given by the equation Δd = 0.1126 + 0.00019 
Aldo, r2 = 0.22 (r = 0.47), p = 0.018 (Figure 2).
To define factors that may independently contrib-
ute to Δd, stepwise regression analysis was performed. 
Factors included in the analysis were other measured 
parameters of cardiovascular function, none of which 
involve time as the primary variable. From the poten-
tially confounding factors BW, Ht, HR, SBP (carotid 
and femoral), DBP (carotid and femoral), LVEDP, 
LVmaxdp/dt, LVmindp/dt, PWV, CVP, ANP, PRA, 
Aldo and Aldo/PRA ratio that may contribute to LV 
contraction duration (Δd) (that best correlated with 
Aldo), femoral DBP (r2 = 0.30, p = 0.004) followed 
in tandem by femoral SBP (r2 = 0.39, p = 0.08), Aldo 
(r2 = 0.48, p = 0.067), BW (r2 = 0.56, p = 0.067), Ht 
(r2 = 0.64, p = 0.05), LVmindp/dt (r2 = 0.74, p = 0.01) 
and PWV (r2 = 0.77, p = 0,18) entered the analysis in-
creasing r2 from 0.30 to 0.77. Therefore from the 77% 
of the explained variance of Δd, 30% is attributed to 
femoral DBP, 9% to femoral SBP, 9% to Aldo, 8% to 
BW, 8% to Ht, 10% to LVmindp/dt and 3% to PWV. 
This means that Aldo is a determinant of Δd and that 
its effect is independent of confounding factors.
DISCUSSION
Cardiovascular and hormonal parameters
Basal cardiovascular parameters were found to be 
Figure 2. Linear regression between Δd and Aldo in healthy 
male rabbits.
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within the limits reported by other investigators10-12. 
Basal levels of PRA (21 ± 7 ng/ml/h) and plasma Aldo 
(69 ± 52 pg/ml) were found to be within the limits 
reported by previous studies: PRA: 29.1 ± 5.7ng/ml/
h13 and Aldo: 27±9 pg/ml to 99±23 pg/ml13-16. Basal 
plasma ANP levels (168 ± 101 pg/ml) were found to 
be about two to three-fold higher than in other studies 
in anesthetized and conscious rabbits: 53.3 ± 4.3pg/
ml17, 61 ± 7 pg/ml18, 59 ± 9.1 pg/ml19, 79 pg/ml20, 76.6 
± 18 pg/ml21. These increased basal levels may be at-
tributed to the relative volume expansion from the iv 
infused N/S solution during the experiment, as well 
as to the irritation of the heart chambers wall by the 
maneuvers for the insertion of the catheter. 
Correlation of Δd with Aldo
In the present study LV contraction duration was mea-
sured using the time interval between LVmaxdp/dt and 
LVmindp/dt (Δd), as was described by Yamamoto et 
al8. This interval measures the systolic time involved 
between just after the closure of mitral valve (point of 
maximal isovolumic contraction rate) and just before 
the closure of aortic valve (point of maximal relaxation 
rate - protodiastole). Classical systolic time intervals 
are the pre-ejection period (PEP), the left ventricular 
ejection time (LVET), and total electromechanical 
systole (QS2) that have already been measured non-
invasively in humans [critically reviewed by Lewis et 
al22] as well as in rabbits12. Since invasive methods are 
used in our study, it was more convenient to use Δd as 
LV contraction duration. Though QS2 equals PEP + 
LVET, Δd incorporates part of PEP and the major part 
of LVET and is therefore minor to QS2.
An interesting finding of our study is the positive 
correlation and the linear regression of Δd with Aldo 
as well as the fact that Aldo contributes by 9% as a 
completely independent factor to Δd (stepwise regres-
Table 1. Cardiovascular and hormonal parameters measured.
Cardiovascular and hormonal parameters (n = 25) X + SD
Heart rate (beats/min) 194 ± 25
Carotid (central) SBP (mmHg) 124 ± 16
Carotid (central)DBP (mmHg) 91 ± 13
Carotid (central)MBP (mmHg) 107 ± 15
Carotid (central) (PP) (mmHg) 31 ± 10
Femoral (peripheral) SBP (mmHg) 123 ± 15
Femoral (peripheral) DBP (mmHg 96 ± 13
Femoral (peripheral) MBP (mmHg) 108 ± 14
Femoral (peripheral) (PP)(mmHg) 26 ± 9
LVPmax (mmHg) 145± 27
LVEDP (mmHg) 8 ± 3
LVmaxdp/dt (mmHg/sec) 3370 ± 872
LVmin dp/dt (mmHg/sec) -2889 ± 862
Δd (sec) 0.125 ± 0.012
LVET (sec) 0.125 ± 0.013
DP (beats / min x mmHg) 23834 ± 3014
CVP (mmHg) -1 ± 2
PWV (cm/sec) 598 ± 120
ANP (pg/ml) 168 ± 101
PRA (ng/ml/h) 21 ± 7
Aldo (pg/ml) 69 ± 52
Aldo to PRA ratio (Aldo/PRA) 3.73 ± 2.81
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sion analysis). Moreover there is no correlation of Δd 
to PRA but only to Aldo/PRA ratio. Lazurova et al23 
found also positive correlation between plasma Aldo 
and LV structural and functional echocardiographic 
parameters (IVSd, PWd, LVIDd and E/A) in hyper-
tensive patients. However no correlation between 
PRA and LV structure and function was found.
In addition to its well-known renal effects, Aldo 
exerts cardiac actions such as blood pressure-indepen-
dent cardiac fibrosis1,24 and LV enlargement1. Apart 
from these presumably genomic effects (requiring 
>10 min to be expressed), Aldo elicits rapid (requir-
ing <10 min to be manifested) nongenomically me-
diated effects2,25,26; it acutely increases systemic vas-
cular resistance3, decreases cardiac output4, affects 
intracellular second messengers such as calcium and 
inositol triphosphate2, induces positive inotropic and 
vasoconstrictor effects in rat heart27 but negative ino-
tropic response in human trabeculae28 and in rabbit 
cardiomyocytes29, decreases the rate of repolarisation 
of atrial muscle fibers30 and increases monophasic ac-
tion potential duration within minutes after iv appli-
cation5. Furthermore, as the observed prolongation 
in monophasic action potential is rapid and waned 
quickly5 and other study31 has suggested that non-ge-
nomic effects lessen despite the continued presence 
of Aldo, acute surges of endogenous Aldo rather than 
persistently elevated levels may be important for these 
effects32. The genomic effects of Aldo are mediated 
via mineralocorticoid receptor (MR). These effects 
involve binding of Aldo to the intracellular MR and 
the translocation of the steroid–MR complex to the 
nucleus, where it acts as a transcriptional regulator, in-
ducing effects after several hours33. The rapid ‘nonge-
nomic’ effects of Aldo (occurring within minutes) are 
likely to be transmitted via specific membrane recep-
tors33. They occur at subnanomolar levels of Aldo and 
involve, among others, inositol 1,4,5-triphosphate 
(IP3), protein kinase C and Ca2+ 34,35. The identity of 
the receptor responsible for the nongenomic effects is 
currently not known.
Since electrical and mechanical events in cardiac 
muscle overlap considerably in time36 it might be 
speculated that the aforementioned nongenomically 
mediated increase of monophasic action potential du-
ration by Aldo would result, by analogy, in (nonge-
Table 2. Correlation of Δd with other measured parameters.
Parameter r p
Femoral (peripheral) DBP (mmHg) -0.55 0.004
Femoral (peripheral) MBP (mmHg) -0.42 0.034
Femoral Pulse Pressure (PP) (mmHg) 0.37 0.069
Aldo (pg/ml) 0.47 0.018
PRA (ng/ml/h) 0.08 0.69
Aldo to PRA ratio (Aldo/PRA) 0.42 0.038
LVET (sec) 0.71 0.0001
Table 3. Correlation of Aldo with other measured parameters.
Parameter r p
Femoral (peripheral) SBP (mmHg) -0.38 0.061
Femoral (peripheral) DBP (mmHg) -0.40 0.046
Femoral (peripheral) MBP (mmHg) -0.37 0.067
LVEDP (mmHg) -0.66 0.0003
Δd (sec) 0.47 0.018
LVET (sec) 0.57 0.003
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nomically mediated) increase of myocardial contrac-
tion duration (Δd). The non-correlation of Δd to PRA 
suggests that the effect may be attributed directly to 
Aldo. Therefore our unexpected finding, from the 
statistical analysis for Aldo, may provide insight into 
another (eventually non-genomic) mechanism of its 
cardiac action, a hypothetical at best, supported only 
indirectly by the found regression. Certainly experi-
mental confirmation of the suggested action is needed 
by iv application of increasing doses of Aldo versus 
cardiovascular parameters over time, including pre-
treatment with classical mineralocorticoid antago-
nists, e.g. spironolactone.
CONClUSION
In the present study a positive correlation and a linear 
regression were found between Aldo and myocardial 
contraction duration (Δd) in healthy NZW anesthe-
tized male rabbits. Peripheral blood pressure (diastolic 
and systolic) and Aldo were the most important deter-
minants of Δd and the effect of Aldo was independent 
of confounding factors. The correlation may provide 
insight into another (eventually nongenomically-
mediated) action of Aldo, but this remains to be es-
tablished experimentally. Thus, any conclusion about 
mechanisms or causality must be strictly identified as 
hypothetical and as a stimulus for further research.
ΠΕΡΙΛΗΨΗ: Εισαγωγή: Η αλδοστερόνη εκτός από τις γνωστές γονιδιακές επιδράσεις [νεφρικές και καρδιακές (ίνωση 
και διάταση)] έχει και μη γονιδιακές δράσεις όπως αύξηση της διάρκειας μονοφασικού μυοκαρδιακού δυναμικού δράσης. 
Κατά την έρευνα της επίδρασης ενδογενών αγγειοδραστικών ουσιών σε καρδιαγγειακές και ορμονικές παραμέτρους σε 25 
φυσιολογικά αρσενικά λευκά κουνέλια Νέας Ζηλανδίας (NZW), παρατηρήθηκε ως τυχαίο εύρημα θετική συσχέτιση μεταξύ 
διάρκειας συστολής αριστερής κοιλίας (ΑΚ) και επιπέδων αλδοστερόνης. 
Υλικό και μέθοδοι: Από την καμπύλη πίεσης της ΑΚ υπολογίσθηκε η μέγιστη και η ελάχιστη ανά μονάδα χρόνου μεταβολή 
της πίεσης (LVmaxdp/dt και LVmindp/dt) και μετρήθηκε ο χρόνος κοιλιακής συστολής δηλ. το χρονικό διάστημα μεταξύ 
LVmaxdp/dt και LVmindp/dt (Δd). 
Αποτελέσματα: Διαπιστώθηκε θετική γραμμική συσχέτιση μεταξύ αλδοστερόνης (που μετρήθηκε με RIA) και Δd 
(Δd = 0,1126 + 0,00019, r = 0,47, p = 0,018). Η ανάλυση πολλαπλών παραγόντων έδειξε ότι οι σημαντικότεροι παράγοντες 
που καθορίζουν τη Δd είναι η (περιφερική) αρτηριακή πίεση και η αλδοστερόνη, της οποίας η επίδραση είναι ανεξάρτητη 
των άλλων παραγόντων. 
Συμπέρασμα: Επειδή ο χρόνος μυοκαρδιακής συστολής διαρκεί όσο και το δυναμικό δράσης, μπορεί να υποτεθεί ότι η μη 
γονιδιακά προκαλούμενη αύξηση της διάρκειας μονοφασικού μυοκαρδιακού δυναμικού δράσης από την αλδοστερόνη, επι-
φέρει αύξηση της διάρκειας της μυοκαρδιακής συστολής, υπόθεση η οποία υποστηρίζεται από τη συσχέτιση που βρέθηκε. 
Λέξεις Κλειδιά: Αλδοστερόνη, Διάρκεια συστολής αρ. κοιλίας, Κουνέλια, Λειτουργία αρ. κοιλίας.
Θετική συσχέτιση επιπέδων αλδοστερόνης  
και διάρκειας συστολής αριστερής κοιλίας σε φυσιολογικά κουνέλια
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